WuXi PharmaTech Strengthens Board with Strategic Appointments of Industry Veterans
核心洞察
WuXi PharmaTech (搜索) has appointed several key executives to its Board of Directors, including Ying Han, Stewart Hen, and co-founder Ning Zhao, bringing valuable financial and pharmaceutical expertise to the company.
The strategic board appointments aim to enhance WuXi's business operations and financial systems as the company continues to expand its pharmaceutical R&D outsourcing services in China and the United States.
Co-founder Tao Lin has stepped down from his position on the board and as Vice President of Internal Operations, marking a significant leadership transition for the growing pharmaceutical services organization.
WuXi PharmaTech (搜索), a leading pharmaceutical R&D outsourcing company with operations in China and the United States, has announced several strategic appointments to its Board of Directors as part of its ongoing efforts to strengthen corporate governance and enhance business operations.
The company appointed Ms. Ying Han to its Board in November, followed by the addition of Mr. Stewart Hen and Dr. Ning Zhao in February, while simultaneously announcing the departure of co-founder Mr. Tao Lin from both the board and his executive position.
Strategic Board Appointments to Drive Growth
Ms. Ying Han brings substantial financial leadership experience to WuXi's board, having served as Chief Financial Officer and Executive Vice President at NASDAQ-listed Asiainfo (搜索) from 1998 to 2006. Prior to that role, she spent a decade at Hewlett Packard (搜索) (China), ultimately holding the position of Chief Controller and Business Development Director. Han holds a degree in Western Accounting from Xiamen University and currently serves as an advisor to Warburg Pincus (搜索), a leading global private equity firm.
Mr. Stewart Hen, a managing director at Warburg Pincus (搜索) LLC, joins the board with over 17 years of life sciences industry experience. His expertise spans investments in biotechnology, pharmaceuticals, and pharmaceutical outsourcing. Before joining Warburg Pincus, Hen worked as a consultant at McKinsey & Company (搜索) serving pharmaceutical clients and previously held positions at Merck (搜索) in both R&D and manufacturing. He holds an MBA from the Wharton School and an MS in chemical engineering from MIT.
Dr. Ning Zhao, one of WuXi's co-founders, brings deep scientific expertise to the board. Currently serving as lead advisor to the company's analytical services operations, she previously held the position of vice president of WuXi's analytical department from 2004 to 2008. Dr. Zhao established several key departments within the company, including Bio-Analytical Services, Core Analytical Services, and Analytical Development Services. Her industry experience includes roles at major pharmaceutical companies such as Wyeth, Pharmacopeia (搜索), and Bristol-Myers Squibb (搜索). A co-inventor on numerous patents with over 36 scientific publications, Dr. Zhao received her Ph.D. from Columbia University and is married to WuXi's Chairman and CEO, Dr. Ge Li.
Leadership Transition as Co-Founder Departs
Concurrent with these appointments, WuXi announced that Mr. Tao Lin, who has served as Vice President of Internal Operations since 2002 and as a director since 2005, has resigned from both positions for personal reasons. As one of the company's founders, Lin played a significant role in WuXi's growth from startup to established industry player.
"I want to personally thank Tao for his counsel and wisdom while serving on our board," said Dr. Ge Li, WuXi's Chairman and Chief Executive Officer. "As a founder and key executive of the company, Tao made many contributions to build WuXi from a start-up to the strong company we are today. We all wish him well."
Enhancing Governance and Business Operations
The board appointments reflect WuXi's commitment to strengthening its corporate governance and business operations as it continues to expand its service offerings in the pharmaceutical, biotechnology, and medical device R&D outsourcing space.
"We are very pleased to welcome Ying on board to further enhance the supervision and conduct of our overall business and financial affairs," commented Dr. Li regarding Han's appointment. "Ying's addition to our board with her invaluable finance and business experience will help WuXi better manage its business and financial system and ultimately increase the overall value of WuXi."
On the appointments of Hen and Zhao, Dr. Li noted, "Each brings invaluable expertise as we work to anticipate and meet our customers' evolving needs for improving R&D productivity."
About WuXi PharmaTech
WuXi PharmaTech (搜索) operates as a research-driven and customer-focused company providing pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. The company's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec, with operations in both China and the United States.